Minetta Liu
Research Collaborator, Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (41)
Purpose: Immune checkpoint blockade (ICB) therapies targeting the PD-1 axis have significantly improved survival in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Circulating tumor DNA (ctDNA) and peripheral T-cell receptor (TCR) repertoires are emerging as promising biomarkers for predicting ICB response. Early characterization of ctDNA and TCR dynamics may enable timely treatment adjustments before clinical or radiologic progression. Experimental Design: The IO-KIN study (NCT04606940) is a single-center, prospective trial involving 15 patients with R/M HNSCC treated with nivolumab or pembrolizumab. Blood samples ( n = 104) were collected across seven time points from baseline to day 29. ctDNA was analyzed using a personalized assay (Signatera), and peripheral TCR repertoires were profiled using CapTCR-seq in eight patients. Results: A decline in ctDNA after day 8 was associated with radiologic response, longer progression-free survival, and a trend toward improved overall survival. TCR repertoires transiently diversified between days 8 and 22, with longer diversification windows in patients showing sustained ctDNA decline. Using the GLIPHII algorithm, an Epstein–Barr virus–specific TCR signature was identified and persisted in patients with clinical benefit. Additional TCR signatures, potentially recognizing tumor-associated antigens, emerged as early as day 3 and were linked to positive outcomes. Conclusions: Simultaneous early monitoring of ctDNA and TCR dynamics reveals key determinants of ICB outcomes in R/M HNSCC. The transient nature of TCR diversification emphasizes the importance of precise sample timing to guide early therapeutic decisions and improve patient outcomes.
Year:
2026
PURPOSE Increased heterogeneity in outcomes has been observed postnephrectomy in patients with renal cell carcinoma (RCC), with standard clinical parameters being primarily used for risk assessment. Currently, no blood-based biomarkers are available for molecular residual disease (MRD) detection in RCC. Herein, we performed a multicenter, real-world evaluation of the prognostic value of circulating tumor DNA (ctDNA) in resected RCC. METHODS This real-world evidence-based multi-institutional study included a cohort of 77 patients with stage I-IV RCC. Longitudinal ctDNA testing was performed on plasma samples (n = 295) using a clinically validated, personalized, tumor-informed ctDNA assay (Signatera, Natera, Inc, Austin, TX). ctDNA results were analyzed, and association with recurrence-free survival was assessed. RESULTS The patient cohort included 77 patients with stage I-IV RCC (clear cell: 64, non–clear cell: 13). Patients who tested ctDNA-positive during the MRD window experienced worse prognosis and a higher likelihood of recurrence (hazard ratios, 18; P < .0001) compared with their ctDNA-negative counterparts. CONCLUSION Overall, we demonstrate the utility of ctDNA testing for MRD detection. Future prospective studies in RCC would be needed to validate the utility of ctDNA in informing clinical decision making.
Year:
2026
ctDNA decrease from C1 to C4 was associated with greater objective response in patients treated with chemoIO at all cutoffs. Number of patients per best objective response with associated increase or decreases in ctDNA between C1 and C4. *Progression-free rate was calculated from the start of therapy rather than the start of C4D1.
Year:
2026
ctDNA decrease from any subsequent cycle was associated with greater objective response in patients treated with chemoIO. Number of patients per best objective response with associated increase or decreases in ctDNA levels between subsequent cycles.
Year:
2026
Biomarker analysis patient cohort characteristics and ITT patient characteristics. Clinical and biomarker characteristics are similar between treatment arms of the biomarker analysis patient cohort evaluated in this study. Clinical and biomarker characteristics are similar between the ITT population in IMpower131 and the biomarker analysis patient cohort evaluated in this study.
Year:
2026
Purpose: Chemoimmunotherapy (chemoIO) is a prevalent first-line treatment for advanced driver-negative non–small cell lung cancer (NSCLC), with maintenance therapy given after induction. However, there is significant clinical variability in the duration, dosing, and timing of maintenance therapy after induction chemoIO. We used circulating tumor DNA (ctDNA) monitoring to inform outcomes in patients with advanced NSCLC receiving chemoIO. Experimental Design: This retrospective study included 221 patients from a phase III trial of atezolizumab+carboplatin+nab-paclitaxel versus carboplatin+nab-paclitaxel in squamous NSCLC (IMpower131). ctDNA monitoring used the FoundationOne Tracker involving comprehensive genomic profiling of pretreatment tumor tissue, variant selection using an algorithm to exclude nontumor variants, and multiplex PCR of up to 16 variants to detect and quantify ctDNA. Results: ctDNA was detected (ctDNA+) in 96% of pretreatment samples (median, 93 mean tumor molecules/mL), and similar ctDNA dynamics were noted across treatment arms during chemoIO. ctDNA decrease from baseline to C4D1 was associated with improved outcomes across multiple cutoffs for patients treated with chemoIO. When including patients with missing plasma or ctDNA- at baseline, patients with ctDNA- at C4D1 (clearance), had more favorable progression-free survival (median 8.8 vs. 3.5 months; HR, 0.32;0.20–0.52) and OS (median not reached vs. 8.9 months; HR, 0.22; 0.12–0.39) from C4D1 than ctDNA+ patients. Conclusions: ctDNA monitoring during induction chemoIO can inform treatment outcomes in patients with advanced NSCLC. Importantly, monitoring remains feasible and informative for patients missing baseline ctDNA. ctDNA testing during induction chemoIO identifies patients at higher risk for disease progression and may inform patient selection for novel personalized maintenance or second-line treatment strategies.
Year:
2026
Purpose: The role of ctDNA in total neoadjuvant therapy (TNT) and nonoperative management (NOM) for locally advanced rectal cancer (LARC) remains unclear. We evaluated the association of ctDNA with clinical outcomes, including treatment response, local regrowth, and distant recurrence in patients undergoing TNT and NOM. Experimental Design: This biomarker companion analysis of the NOMINATE trial, a prospective, multicenter, randomized phase II study, enrolled 64 patients with T3 to T4NanyM0 LARC between March 2021 and July 2023. Plasma samples ( n = 412) were collected at multiple time points: pretreatment (T0), interim evaluations (T1 and T2), final re-staging (T3), and after surgery or after NOM (T4 and beyond). ctDNA was monitored using a tumor-informed multiplex polymerase chain reaction–next generation sequencing assay (Signatera). The association between ctDNA status and clinical outcomes was analyzed. Results: Baseline ctDNA detection was 98.4%, which decreased to 32% at T1, 15% at T2, 30% at T3, and 5% at T4. Among 25 patients achieving clinical complete response (cCR) or near cCR with NOM, ctDNA clearance was 100% at T2 to T4, whereas 39 non-cCR patients showed lower clearance rates (75% at T2 and 51% at T3). ctDNA at T3 had 100% specificity and positive predictive value for pathologic residual disease and was associated with shorter disease-free survival (HR = 6.7, P = 0.005). Local regrowth occurred in five NOM patients, with ctDNA detected in two during surveillance. Conclusions: This study highlights the potential of ctDNA as a predictive and prognostic biomarker in patients with LARC undergoing TNT and subsequently managed by NOM. However, the modest sensitivity of ctDNA highlights the need for technological improvements. See related commentary by Bent et al., p. 5117
Year:
2025
Kaplan–Meier estimates for PFS (A) and OS (B) stratified by ctDNA status post/during ICI treatment. (C) BOR (CR, PR, SD, and PD) stratified based on ctDNA status post/during ICI treatment. In A and B, hazard ratios for PFS and OS have been adjusted for ECOG (0 vs 1/2), p16 status (negative vs positive), and the location of recurrence (locoregional only versus distant metastases). ctDNA: circulating tumor DNA; ICI: immune checkpoint inhibitor; HR: Hazard Ratio; PFS: Progression-free Survival; OS: overall survival; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease.
Year:
2025
Purpose: Although immunotherapy improves the overall survival (OS) of patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN), only 15% to 20% of patients derive a long-term benefit. We hypothesized that ctDNA kinetics during immunotherapy, with or without chemotherapy, could predict treatment efficacy in patients with R/M SCCHN. Experimental Design: Using a personalized, tumor-informed ctDNA assay, we evaluated ctDNA kinetics from pre- to on-treatment (6–10 weeks after treatment initiation) time points. The primary endpoint was the concordance between ctDNA kinetics and best overall response (BOR). Secondary endpoints were the association of ctDNA clearance and kinetics with OS and progression-free survival (PFS). Results: Of the 41 patients, ctDNA assays were successfully designed for 29, and ctDNA was detected before treatment in 25 patients. ctDNA kinetics was significantly correlated with BOR ( P = 0.00032). Patients with unfavorable ctDNA kinetics had significantly worse PFS compared with those with favorable ctDNA kinetics (HR = 16.98; 95% confidence interval, 3.35–86.1; P = 0.0006). Six patients had ctDNA clearance, all of whom presented a complete or partial response as BOR. PFS and OS were significantly improved in patients with ctDNA clearance compared with those without clearance (PFS: P = 0.0006, OS: P = 0.027). Conclusions: ctDNA kinetics, assessed with a tumor-informed assay, can predict anti–PD-1 therapy efficacy in R/M SCCHN. Early ctDNA clearance during the initial weeks of immunotherapy seems to be a strong predictive marker for a favorable response, as well as improved PFS and OS.
Year:
2025
Relationship between ctDNA kinetics and best overall response (BOR) stratified by immune checkpoint inhibitor type. Stacked bar plots illustrating the distribution of best overall response (BOR: complete response [CR], partial response [PR], stable disease [SD], and progressive disease [PD]) according to ctDNA kinetics (favorable vs. unfavorable) separately for patients treated with nivolumab (n = 8) (A) and pembrolizumab (n = 17) (B). Favorable ctDNA kinetics was defines as >20% of decrease in ctDNA levels; unfavorable ctDNA kinetics included
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (80)
William Huang
Professor (Clinical)
New York University Grossman School of Medicine
Samuel Klempner
Associate Professor
Massachusetts General Hospital
Thierry André
Sorbonne Université
Aaron R. Hansen
Medical Oncologist
University Health Network
Sean Park
Professor
Mayo Clinic Rochester
Jianjun Gao
Assistant Professor
The University of Texas MD Anderson Cancer Center
Catherine Alix-Panabières
Director/Professor
University Hospital of Montpellier
Paola Gazzaniga
Sapienza University of Rome
Jérôme Galon
Research Director
INSERM
Daniel F. Hayes
Stuart B. Padnos Professor of Breast Cancer Research
University of Michigan Rogel Cancer Center
Michail Ignatiadis
Leader Investigator Initiated Trials
Institut Jules Bordet
Kohei Shigeta
Assistant Professor
Keio University School of Medicine
Takashi Akiyoshi
The Cancer Institute Hospital
Siang-Boon Koh
Academic , Senior Lecturer
University Hospitals Bristol and Weston NHS Foundation Trust
Justin M. Balko
Vanderbilt University Medical Center
Anna Spreafico
University Health Network
Roni Wilke
The University of Texas MD Anderson Cancer Center
Anil Sood
Professor
The University of Texas MD Anderson Cancer Center
Daniel D. Billadeau
-
Sanghoon Lee
Associate Professor
The University of Texas MD Anderson Cancer Center
Lisa Anne Carey
Deputy Director for Clinical Science
University of North Carolina at Chapel Hill
Amir Jazaeri
Professor
The University of Texas MD Anderson Cancer Center
Adrian V. Lee
University of Pittsburgh
Steffi Oesterreich
UPMC Hillman Cancer Center
Pamela S. Ohashi
University of Toronto
Jeffrey How
Assistant Professor
The University of Texas MD Anderson Cancer Center
Arnab Basu
The University of Alabama at Birmingham School of Medicine
Lillian L. Siu
University Health Network
Chetan Bettegowda
Johns Hopkins University School of Medicine
Aaron Mansfield
Mayo Clinic Minnesota
Leif Ellisen
Professor and Program Director, Breast Oncology
Massachusetts General Hospital
Allan Hackshaw
University College London
Francois-Clement Bidard
Professor of Medical Oncology
Institut Curie
Yibo Dai
The University of Texas MD Anderson Cancer Center
Jean-François Emile
Université de Versailles Saint-Quentin-en-Yvelines
Shannon Westin
The University of Texas MD Anderson Cancer Center
Tomasz Michal Beer
Oregon Health & Science University
Hope Rugo
Director, Women’s Cancer Program Division; Professor, Department of Medical Oncology & Therapeutics Research; Chief, Breast Medical Oncology
City Of Hope National Medical Center
Jean-Yves Pierga
Head of Department
Institut Curie
Karthik Giridhar
Assistant Professor
Mayo Clinic
Tanja Fehm
Professor
University Hospital Düsseldorf
Carlos Caldas
Professor
Hebrew University of Jerusalem
Haidong Dong
Professor/Consultant
Mayo Clinic Rochester
Gwyn Richardson
Professor
The University of Texas MD Anderson Cancer Center
Jennifer A. Wargo
The University of Texas MD Anderson Cancer Center
Gillian Hirst
Associate Professor
University of California, San Francisco
Leon W. M. M. Terstappen
University of Twente
James Ferguson
Assistant Professor
The University of Alabama
Srinivasvinod Saladi
Associate Professor
University of Toledo Medical Center
Elisabetta Munzone
Director
European Institute of Oncology
Manoj Chelvanambi
The University of Texas MD Anderson Cancer Center
Pamela Soliman
Associate Professor
The University of Texas MD Anderson Cancer Center
Cara Haymaker
Associate Professor
The University of Texas MD Anderson Cancer Center
Andres Ocampo
Vanderbilt University
julien taieb
Professor Head of the department
Université Paris-Saclay
Justin Stebbing
Professor
Imperial College London
Michael Gibson
Vanderbilt University Medical Center
Evi Lianidou
PROFESSOR
National and Kapodistrian University of Athens
Laura Esserman
University of California
Cathy Eng
Professor; Associate Director for Strategic Relations and Research Partnerships
Vanderbilt University Medical Center
Ying Yuan
Professor
The University of Texas MD Anderson Cancer Center
Trevor J. Pugh
Professor
University Health Network
Aditya Bardia
UCLA Health
Kai Wucherpfennig
Professor and Department Chair
Dana-Farber Cancer Institute
Erica Mayer
Dana-Farber Cancer Institute
Alexander Lazar
Professor
The University of Texas MD Anderson Cancer Center
Massimo Cristofanilli
Professor of Medicine
Weill Cornell Medicine
Laura J. van 't Veer
University of California, San Francisco
Julia Foldi
Assistant Professor of Medicine
University of Pittsburgh School of Medicine
LAMORNA SWIGART
University of California, San Francisco
Cédric van Marcke
-
Klaus Pantel
-
Rana R. McKay
University of California, San Diego
Pierre Laurent-Puig
Université Paris Descartes
Linghua Wang
Executive Director & Head
The University of Texas MD Anderson Cancer Center
Soroush Rais-Bahrami
The University of Alabama at Birmingham School of Medicine
David Boruta
Professor
The University of Texas MD Anderson Cancer Center
Markus Wallwiener
University Hospital Heidelberg
DANIELE GENERALI
University of Trieste
Kostandinos Sideras
Assistant Professor
Mayo Clinic
Make your next move.
Prepare your application
Review drafts before you send them.